UPDATE: Aegis Capital Starts Entera Bio Ltd (ENTX) at Buy
- Dow hits milestone, S&P breaks record high on tech rally
- Thermo Fisher Scientific (TMO) to Acquire PPD, Inc. (PPD) for $47.50/sh, $17.4 Billion
- U.S. retail sales post largest gain in 10 months; weekly jobless claims fall
- The Stock Market is Almost 'Completely Broken' - Einhorn
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - March 22, 2021 10:40 AM EDT)
(Updated to add company name)
Aegis Capital analyst Nathan Weinstein initiates coverage on Entera Bio Ltd (NASDAQ: ENTX) with a Buy rating and a price target of $12.00.
Analyst says: "Our PT is based on a discounted cash flow analysis using an 20% discount rate and 58% PoS. We credit future potential revenue in EB613, while treating the balance of the pipeline as option value at this time."
Shares of closed at $4.57 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Entera Bio Ltd. (ENTX) Names Ramesh Ratan CFO
- Aegis Capital Starts Immunic Inc. (IMUX) at Buy
- UPDATE: Deutsche Bank Starts CrowdStrike Holdings (CRWD) at Buy